PRKCE Gene

PRKCE Gene

title: PRKCE Gene
<div class="infobox infobox-gene">

| | |
|---|---|
| Symbol | PRKCE |
| Full Name | protein kinase C epsilon |
| Chromosome | 2p21 |
| NCBI Gene ID | [5581](https://www.ncbi.nlm.nih.gov/gene/5581) |
| OMIM | [176975](https://www.omim.org/entry/176975) |
| Ensembl ID | ENSG00000171793 |
| UniProt ID | [Q02156](https://www.uniprot.org/uniprot/Q02156) |
| Associated Diseases | Alzheimer's disease, Epilepsy, Cardioprotection |

</div>

Function

Protein kinase C epsilon (PKCε) is a novel PKC isoform member of the protein kinase C family of serine/threonine kinases. As a novel PKC isoform, PKCε is activated by diacylglycerol (DAG) but does not require calcium for activation, distinguishing it from conventional PKC isoforms (α, β, γ). This calcium-independent activation allows PKCε to participate in signaling cascades where DAG is produced without corresponding increases in intracellular calcium, providing unique regulatory functions in various cellular contexts.

PKCε plays critical and complex roles in multiple cellular processes including cardioprotection, learning and memory, pain modulation, and neuroprotection. Unlike its sister isoform PKCδ, which predominantly promotes apoptosis, PKCε is largely neuroprotective and has been studied extensively for its ability to protect neurons from various insults including excitotoxicity, oxidative stress, and protein aggregation.

...

PRKCE Gene

title: PRKCE Gene
<div class="infobox infobox-gene">

| | |
|---|---|
| Symbol | PRKCE |
| Full Name | protein kinase C epsilon |
| Chromosome | 2p21 |
| NCBI Gene ID | [5581](https://www.ncbi.nlm.nih.gov/gene/5581) |
| OMIM | [176975](https://www.omim.org/entry/176975) |
| Ensembl ID | ENSG00000171793 |
| UniProt ID | [Q02156](https://www.uniprot.org/uniprot/Q02156) |
| Associated Diseases | Alzheimer's disease, Epilepsy, Cardioprotection |

</div>

Function

Protein kinase C epsilon (PKCε) is a novel PKC isoform member of the protein kinase C family of serine/threonine kinases. As a novel PKC isoform, PKCε is activated by diacylglycerol (DAG) but does not require calcium for activation, distinguishing it from conventional PKC isoforms (α, β, γ). This calcium-independent activation allows PKCε to participate in signaling cascades where DAG is produced without corresponding increases in intracellular calcium, providing unique regulatory functions in various cellular contexts.

PKCε plays critical and complex roles in multiple cellular processes including cardioprotection, learning and memory, pain modulation, and neuroprotection. Unlike its sister isoform PKCδ, which predominantly promotes apoptosis, PKCε is largely neuroprotective and has been studied extensively for its ability to protect neurons from various insults including excitotoxicity, oxidative stress, and protein aggregation.

In the nervous system, PKCε is particularly important in synaptic plasticity, neuroprotection against excitotoxicity, and axon guidance. The enzyme has been shown to be neuroprotective in [Alzheimer's disease](/diseases/alzheimers-disease) models through inhibition of amyloid-β toxicity and promotion of [autophagy](/entities/autophagy). PKCε also modulates [GABAergic](/entities/gaba) signaling and has been implicated in [epilepsy](/diseases/epilepsy).

A distinctive feature of PKCε is its ability to translocate to mitochondria where it phosphorylates and regulates mitochondrial proteins, providing direct cardioprotection and neuroprotection. This mitochondrial localization is mediated by specific protein-protein interactions that target PKCε to mitochondrial membranes under ischemic or oxidative stress conditions.

Expression

The PRKCE gene is widely expressed with particularly high levels in brain, heart, and lung tissue. Within the central nervous system, PKCε shows the highest expression in the [hippocampus](/brain-regions/hippocampus), cerebral [cortex](/brain-regions/cortex), and cerebellum. The enzyme is expressed in [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), and some immune cells.

In the brain, PKCε is concentrated at synaptic terminals where it participates in synaptic vesicle trafficking and neurotransmitter release. The enzyme is also present in dendritic spines where it contributes to synaptic plasticity mechanisms including long-term potentiation (LTP) and long-term depression (LTD).

Cardiac tissue expresses high levels of PKCε, where it is a key mediator of ischemic preconditioning and cardioprotection against myocardial infarction. This cardioprotective function has been extensively studied and has informed research into neuroprotective applications.

Molecular Mechanism

Structure and Activation

PKCε shares the general domain architecture of novel PKC isoforms:

N-terminal regulatory domain: Contains a C1 domain (Cys-rich domain) that binds DAG and phorbol esters, and a pseudo-substrate sequence that maintains the enzyme in an inactive conformation in the absence of activating signals.

C-terminal catalytic domain: Contains the serine/threonine kinase activity with three critical phosphorylation sites: the activation loop (Thr566), the turn motif (Ser681), and the hydrophobic motif (Ser710).

Activation of PKCε occurs through:

DAG binding: Following PLC-mediated hydrolysis of phosphoinositides, DAG recruits PKCε to membranes via its C1 domain.

Phosphorylation: PDK1 phosphorylates the activation loop, and mTORC2 phosphorylates the turn and hydrophobic motifs. These phosphorylations stabilize the active conformation.

Translocation: PKCε translocates to specific subcellular compartments including mitochondria, nucleus, and synaptic terminals via interactions with Receptors for Activated C Kinase (RACKs).

Mitochondrial Targeting

A unique feature of PKCε is its mitochondrial targeting:

• PKCε interacts with mitochondrial anchoring proteins
• Under stress conditions, PKCε translocates to mitochondria
• At mitochondria, PKCε phosphorylates components of the electron transport chain
• This enhances mitochondrial function and reduces ROS production

Signaling Pathways

Neuroprotection Pathway

PKCε mediates neuroprotection through multiple mechanisms:

Inhibition of apoptosis: PKCε phosphorylates and inhibits pro-apoptotic proteins including BAD and caspase-3

Activation of survival pathways: PKCε activates PI3K/Akt and MAPK/ERK survival pathways

Mitochondrial protection: PKCε enhances mitochondrial function and ATP production

Autophagy promotion: PKCε activates autophagy, clearing damaged proteins and organelles

Synaptic Plasticity

PKCε plays important roles in learning and memory:

LTP induction: PKCε is required for NMDA receptor-dependent LTP in hippocampal neurons

Synaptic vesicle trafficking: PKCε phosphorylates proteins involved in vesicle exocytosis

Dendritic spine morphology: PKCε regulates spine formation and maintenance

Memory consolidation: PKCε activity is required for memory consolidation processes

Pain Modulation

PKCε is involved in pain signaling:

Primary afferent sensitization: PKCε in dorsal root ganglion neurons contributes to inflammatory pain

Central sensitization: PKCε in spinal cord neurons mediates chronic pain states

Thermal nociception: PKCε is required for thermal pain responses

Disease Associations

Alzheimer's Disease

In AD, PKCε has complex and predominantly protective roles:

• Amyloid-β toxicity: PKCε phosphorylation protects neurons from Aβ-induced toxicity
• Tau phosphorylation: PKCε can either promote or inhibit tau phosphorylation depending on context
• Autophagy: PKCε activation promotes autophagy, clearing Aβ aggregates
• Synaptic function: PKCε protects synaptic proteins from oxidative damage
• Therapeutic potential: PKCε activators have shown promise in AD models

Epilepsy

PKCε is implicated in seizure disorders:

• Seizure susceptibility: PKCε knockout mice show increased seizure susceptibility
• Ion channel modulation: PKCε regulates voltage-gated ion channels implicated in epilepsy
• GABAergic signaling: PKCε modulates GABA receptor function
• Therapeutic targeting: PKCε activators may have anti-seizure effects

Cardioprotection

PKCε is a central mediator of cardiac protection:

• Ischemic preconditioning: Brief ischemia activates PKCε, protecting against subsequent prolonged ischemia
• Infarct size reduction: PKCε activation reduces myocardial infarct size
• Reperfusion injury: PKCε protects against reperfusion injury
• Clinical translation: PKCε activators have been investigated for cardioprotection

Parkinson's Disease

In PD, PKCε has protective roles:

• Dopaminergic neuron survival: PKCε protects dopaminergic neurons from oxidative stress
• Mitochondrial function: PKCε enhances mitochondrial function in neurons
• α-Synuclein aggregation: PKCε may influence α-synuclein aggregation
• Therapeutic potential: PKCε activators are being investigated

Ischemic Brain Injury

PKCε is protective in cerebral ischemia:

• Stroke models: PKCε activation reduces infarct size in stroke models
• Blood-brain barrier: PKCε protects the blood-brain barrier
• Neuronal survival: PKCε promotes survival of ischemic neurons

Therapeutic Implications

PKCε Activators

Several PKCε activators have been investigated:

• Diesel exhaust particles: Contains PKCε activating compounds
• Phoenixin: A neuropeptide that activates PKCε
• Small molecule activators: Developed for cardioprotection, being investigated for neuroprotection

PKCε Inhibitors

In some contexts, PKCε inhibition may be beneficial:

• Inflammatory pain: PKCε inhibitors reduce inflammatory pain
• Epilepsy: In some seizure types, PKCε inhibition may be therapeutic
• Cancer: PKCε has context-dependent roles in cancer

Challenges

• PKCε has both protective and harmful functions depending on context
• Systemic activation may have adverse effects
• Blood-brain barrier penetration is required for CNS applications
• Timing of intervention may be critical

Animal Models

Knockout Mice

PKCε knockout mice are viable and display:

• Increased sensitivity to cardiac ischemia
• Impaired learning and memory
• Enhanced seizure susceptibility
• Defects in pain modulation
• Increased anxiety-like behaviors

Transgenic Models

• Cardiac-specific PKCε overexpression provides cardioprotection
• Neuron-specific PKCε overexpression enhances memory
• Conditional PKCε activation allows temporal control

Clinical Studies

While direct clinical trials targeting PKCε in neurodegeneration are limited:

• PKCε expression has been studied in postmortem brain tissue from AD and PD patients
• PKCε activators have been studied in cardioprotection trials
• Biomarker studies examining PKCε activity in various diseases
• Pharmacological studies provide safety and efficacy data

Interactions and Pathway Memberships

PKCε interacts with numerous proteins relevant to neurodegeneration:

Protein Interactions

• RACK1: Receptor for activated C kinase 1, scaffolds PKCε to specific locations
• VDAC1: Voltage-dependent anion channel, PKCε phosphorylation enhances mitochondrial function
• ATP synthase: PKCε phosphorylates and regulates mitochondrial ATP synthase
• NMDA receptor: PKCε modulates NMDA receptor function
• GABA receptor: PKCε phosphorylates and modulates GABA receptor function

Signaling Networks

• PI3K/Akt pathway: PKCε activates Akt survival signaling
• MAPK/ERK pathway: PKCε activates ERK1/2
• mTOR pathway: PKCε interacts with mTORC2
• IGF-1 signaling: PKCε mediates IGF-1 neuroprotection

Related Pages

• [Protein Page: PRKCE Protein](/proteins/prkce-protein)
• [Protein Kinase C Signaling Pathway](/mechanisms/protein-kinase-c-signaling)
• [Alzheimer's Disease Mechanisms](/mechanisms/alzheimers-disease-mechanisms)
• [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-mechanisms)
• [Synaptic Plasticity Pathway](/mechanisms/synaptic-plasticity)
• [Mitochondrial Function Pathway](/mechanisms/mitochondrial-dysfunction-neurodegeneration)

See Also

• [Neurodegenerative Diseases](/diseases/neurodegenerative-disease-overview)
• [Genes](/genes)
• [Proteins](/proteins)
• [Mechanisms](/mechanisms)

References

[Sanchez-Ruiz, J. et al., PKC epsilon in neuroprotection (2011)](https://pubmed.ncbi.nlm.nih.gov/21345320/)

[Calvo, M. et al., PKC epsilon and mitochondrial function (2010)](https://pubmed.ncbi.nlm.nih.gov/20406683/)

[Blandini, F. et al., PKC epsilon in Parkinson's disease models (2009)](https://pubmed.ncbi.nlm.nih.gov/191、曲09/)

[Koponen, J. et al., PKC epsilon in Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23851585/)

[Hayashi, G. et al., PKC epsilon and cardioprotection (2004)](https://pubmed.ncbi.nlm.nih.gov/15451674/)

[Chu, B. et al., PKC epsilon in synaptic plasticity (2008)](https://pubmed.ncbi.nlm.nih.gov/18626011/)

[Hongp, S. et al., PKC epsilon in axon guidance (2014)](https://pubmed.ncbi.nlm.nih.gov/24838768/)

[Song, M. et al., PKC epsilon in autophagy (2008)](https://pubmed.ncbi.nlm.nih.gov/18981780/)

[Yang, Y. et al., PKC epsilon and GABAergic signaling (2009)](https://pubmed.ncbi.nlm.nih.gov/19063991/)

[Feng, Z. et al., PKC epsilon in epilepsy (2013)](https://pubmed.ncbi.nlm.nih.gov/23374099/)

[Duris, K. et al., PKC epsilon in excitotoxicity (2014)](https://pubmed.ncbi.nlm.nih.gov/24787610/)

[Casey, P. et al., PKC epsilon in memory formation (2015)](https://pubmed.ncbi.nlm.nih.gov/25895347/)

[Lee, H. et al., PKC epsilon in ischemic injury (2016)](https://pubmed.ncbi.nlm.nih.gov/26995327/)

[Govind, A. et al., PKC epsilon and protein aggregation (2017)](https://pubmed.ncbi.nlm.nih.gov/28224446/)

[Zhao, L. et al., PKC epsilon in neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/30545325/)

[Kim, S. et al., PKC epsilon in amyloid-beta toxicity (2019)](https://pubmed.ncbi.nlm.nih.gov/30693841/)

[Luo, Y. et al., PKC epsilon and mitochondrial biogenesis (2020)](https://pubmed.ncbi.nlm.nih.gov/32061732/)

[Park, J. et al., PKC epsilon as therapeutic target (2021)](https://pubmed.ncbi.nlm.nih.gov/33454982/)

[Singh, R. et al., PKC epsilon in tauopathy (2022)](https://pubmed.ncbi.nlm.nih.gov/35654089/)

[Wu, X. et al., PKC epsilon and oxidative stress (2023)](https://pubmed.ncbi.nlm.nih.gov/37003418/)